MAS825, -
CMAS825J12201
Phase 2 small_molecule active
Quick answer
MAS825, - for Still’s disease is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Still’s disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active